Clinical Trials Directory

Trials / Terminated

TerminatedNCT02530307

HT-3951 vs. Placebo in Stroke Rehabilitation

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
61 (actual)
Sponsor
Dart NeuroScience, LLC · Industry
Sex
All
Age
21 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This is a randomized, double-blind, placebo-controlled parallel group outpatient study that will utilize standard stroke rehabilitation outcome measures, as well as fMRI techniques in a subset of subjects, to evaluate the effect of HT-3951 on motor recovery and behavior in medically stable subjects following ischemic stroke.

Conditions

Interventions

TypeNameDescription
DRUGHT-3951
DRUGPlacebo

Timeline

Start date
2016-02-01
Primary completion
2017-12-31
Completion
2017-12-31
First posted
2015-08-21
Last updated
2018-02-01

Locations

18 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02530307. Inclusion in this directory is not an endorsement.